Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants
Since its emergence as a pneumonia-like outbreak in the Chinese city of Wuhan in late
2019, the novel coronavirus disease COVID-19 has spread widely to become a global …
2019, the novel coronavirus disease COVID-19 has spread widely to become a global …
[HTML][HTML] Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection
rates, cumulative infections, the proportion of the population that has been infected at least …
rates, cumulative infections, the proportion of the population that has been infected at least …
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
A Tauzin, M Nayrac, M Benlarbi, SY Gong, R Gasser… - Cell host & …, 2021 - cell.com
While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses …
doses administered 3 weeks apart, some public health authorities are spacing these doses …
Structure-function analyses of new SARS-CoV-2 variants B. 1.1. 7, B. 1.351 and B. 1.1. 28.1: clinical, diagnostic, therapeutic and public health implications
SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2) has accumulated
multiple mutations during its global circulation. Recently, three SARS-CoV-2 lineages, B …
multiple mutations during its global circulation. Recently, three SARS-CoV-2 lineages, B …
[HTML][HTML] Symptomatic reinfection of SARS‐CoV‐2 with spike protein variant N440K associated with immune escape
Dear Editor, A number of cases of reinfections in individuals with SARS‐CoV‐2 have
emerged across the globe. 1, 2 With the emergence of genetic variants associated with …
emerged across the globe. 1, 2 With the emergence of genetic variants associated with …
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
A Tauzin, M Nayrac, M Benlarbi, SY Gong, R Gasser… - Biorxiv, 2021 - biorxiv.org
The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical
trials includes two doses administered three weeks apart. While the decision by some public …
trials includes two doses administered three weeks apart. While the decision by some public …
Variants of concern responsible for SARS‐CoV‐2 vaccine breakthrough infections from India
Emerging reports of SARS‐CoV‐2 breakthrough infections entail methodical genomic
surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis …
surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis …
Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka
C Pattabiraman, P Prasad, AK George… - Wellcome Open …, 2022 - pmc.ncbi.nlm.nih.gov
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, the
selection of genomic variants of severe acute respiratory syndrome coronavirus 2 (SARS …
selection of genomic variants of severe acute respiratory syndrome coronavirus 2 (SARS …
[HTML][HTML] COVID-19 mutations: An overview
M Sarkar, I Madabhavi - World Journal of Methodology, 2024 - pmc.ncbi.nlm.nih.gov
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to the genus
Beta coronavirus and the family of Coronaviridae. It is a positive-sense, non-segmented …
Beta coronavirus and the family of Coronaviridae. It is a positive-sense, non-segmented …